These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 24633735)

  • 1. Differential LRRK2 expression in the cortex, striatum, and substantia nigra in transgenic and nontransgenic rodents.
    West AB; Cowell RM; Daher JP; Moehle MS; Hinkle KM; Melrose HL; Standaert DG; Volpicelli-Daley LA
    J Comp Neurol; 2014 Aug; 522(11):2465-80. PubMed ID: 24633735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LRRK2 BAC transgenic rats develop progressive, L-DOPA-responsive motor impairment, and deficits in dopamine circuit function.
    Sloan M; Alegre-Abarrategui J; Potgieter D; Kaufmann AK; Exley R; Deltheil T; Threlfell S; Connor-Robson N; Brimblecombe K; Wallings R; Cioroch M; Bannerman DM; Bolam JP; Magill PJ; Cragg SJ; Dodson PD; Wade-Martins R
    Hum Mol Genet; 2016 Mar; 25(5):951-63. PubMed ID: 26744332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. (G2019S) LRRK2 causes early-phase dysfunction of SNpc dopaminergic neurons and impairment of corticostriatal long-term depression in the PD transgenic mouse.
    Chou JS; Chen CY; Chen YL; Weng YH; Yeh TH; Lu CS; Chang YM; Wang HL
    Neurobiol Dis; 2014 Aug; 68():190-9. PubMed ID: 24830390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Behavioral, neurochemical, and pathologic alterations in bacterial artificial chromosome transgenic G2019S leucine-rich repeated kinase 2 rats.
    Lee JW; Tapias V; Di Maio R; Greenamyre JT; Cannon JR
    Neurobiol Aging; 2015 Jan; 36(1):505-18. PubMed ID: 25174649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
    Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ
    Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S.
    Li X; Patel JC; Wang J; Avshalumov MV; Nicholson C; Buxbaum JD; Elder GA; Rice ME; Yue Z
    J Neurosci; 2010 Feb; 30(5):1788-97. PubMed ID: 20130188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Age- and Sex-Dependent Behavioral and Neurochemical Alterations in hLRRK2-G2019S BAC Mice.
    Yao N; Skiteva O; Chergui K
    Biomolecules; 2022 Dec; 13(1):. PubMed ID: 36671436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LRRK2 expression is enriched in the striosomal compartment of mouse striatum.
    Mandemakers W; Snellinx A; O'Neill MJ; de Strooper B
    Neurobiol Dis; 2012 Dec; 48(3):582-93. PubMed ID: 22850484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temporal expression of mutant LRRK2 in adult rats impairs dopamine reuptake.
    Zhou H; Huang C; Tong J; Hong WC; Liu YJ; Xia XG
    Int J Biol Sci; 2011; 7(6):753-61. PubMed ID: 21698001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. G2019S LRRK2 and aging confer susceptibility to proteasome inhibitor-induced neurotoxicity in nigrostriatal dopaminergic system.
    Xiao Q; Yang S; Le W
    J Neural Transm (Vienna); 2015 Dec; 122(12):1645-57. PubMed ID: 26253900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. (G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD.
    Chen CY; Weng YH; Chien KY; Lin KJ; Yeh TH; Cheng YP; Lu CS; Wang HL
    Cell Death Differ; 2012 Oct; 19(10):1623-33. PubMed ID: 22539006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of the LRRK2 gene in the midbrain dopaminergic neurons of the substantia nigra.
    Han BS; Iacovitti L; Katano T; Hattori N; Seol W; Kim KS
    Neurosci Lett; 2008 Sep; 442(3):190-4. PubMed ID: 18634852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Altered Development of Synapse Structure and Function in Striatum Caused by Parkinson's Disease-Linked LRRK2-G2019S Mutation.
    Matikainen-Ankney BA; Kezunovic N; Mesias RE; Tian Y; Williams FM; Huntley GW; Benson DL
    J Neurosci; 2016 Jul; 36(27):7128-41. PubMed ID: 27383589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopaminergic neurodegeneration induced by Parkinson's disease-linked G2019S LRRK2 is dependent on kinase and GTPase activity.
    Nguyen APT; Tsika E; Kelly K; Levine N; Chen X; West AB; Boularand S; Barneoud P; Moore DJ
    Proc Natl Acad Sci U S A; 2020 Jul; 117(29):17296-17307. PubMed ID: 32631998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Localization of Parkinson's disease-associated LRRK2 in normal and pathological human brain.
    Higashi S; Biskup S; West AB; Trinkaus D; Dawson VL; Faull RL; Waldvogel HJ; Arai H; Dawson TM; Moore DJ; Emson PC
    Brain Res; 2007 Jun; 1155():208-19. PubMed ID: 17512502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The C-terminal domain of LRRK2 with the G2019S mutation is sufficient to produce neurodegeneration of dopaminergic neurons in vivo.
    Cresto N; Gaillard MC; Gardier C; Gubinelli F; Diguet E; Bellet D; Legroux L; Mitja J; Auregan G; Guillermier M; Josephine C; Jan C; Dufour N; Joliot A; Hantraye P; Bonvento G; Déglon N; Bemelmans AP; Cambon K; Liot G; Brouillet E
    Neurobiol Dis; 2020 Feb; 134():104614. PubMed ID: 31605779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparative analysis of leucine-rich repeat kinase 2 (Lrrk2) expression in mouse brain and Lewy body disease.
    Melrose HL; Kent CB; Taylor JP; Dachsel JC; Hinkle KM; Lincoln SJ; Mok SS; Culvenor JG; Masters CL; Tyndall GM; Bass DI; Ahmed Z; Andorfer CA; Ross OA; Wszolek ZK; Delldonne A; Dickson DW; Farrer MJ
    Neuroscience; 2007 Jul; 147(4):1047-58. PubMed ID: 17611037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parkinson's disease-related Leucine-rich repeat kinase 2 modulates nuclear morphology and genomic stability in striatal projection neurons during aging.
    Chen X; Xie C; Tian W; Sun L; Zheng W; Hawes S; Chang L; Kung J; Ding J; Chen S; Le W; Cai H
    Mol Neurodegener; 2020 Feb; 15(1):12. PubMed ID: 32075681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice.
    Longo F; Mercatelli D; Novello S; Arcuri L; Brugnoli A; Vincenzi F; Russo I; Berti G; Mabrouk OS; Kennedy RT; Shimshek DR; Varani K; Bubacco L; Greggio E; Morari M
    Acta Neuropathol Commun; 2017 Mar; 5(1):22. PubMed ID: 28292328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of LRRK2 Inhibitors on Nigrostriatal Dopaminergic Neurotransmission.
    Qin Q; Zhi LT; Li XT; Yue ZY; Li GZ; Zhang H
    CNS Neurosci Ther; 2017 Feb; 23(2):162-173. PubMed ID: 27943591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.